Researchers conducted an open-label extension study to assess the efficacy of first-line ofatumumab treatment up to 6 years in patients with relapsing multiple sclerosis.

In MS, progression independent of relapse activity is associated with neurodegenerative processes in the spinal cord and the ...

A subcutaneous (under-the-skin) formulation of Ocrevus (ocrelizumab) helped most adults with multiple sclerosis (MS) remain ...

For recent MS patients, first-line Kesimpta treatment was tied to a lower risk of disability progression compared with using ...

(RTTNews) - Novartis AG (NVS) said that an analysis of treatment-naive people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six ...

Data from the Phase III OCARINA II study shows the subcutaneous version of Ocrevus achieved near-complete suppression of ...

Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant ...

“Our analysis of treatment-naïve people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six years provided long-term ...

TG Therapeutics' nearly $50.5 million in first-quarter product revenue derived entirely from sales of its drug Briumvi, which treats relapsing multiple sclerosis (RMS). Combining that with license ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients ...

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosisData support frexalimab as a potential ...